Federal Register / Vol. 73, No. 173 / Friday, September 5, 2008 / Notices 51819 

1Copies of the Minutes of the Federal Open 

Market Committee meeting on August 5, 2008, 

which includes the domestic policy directive issued 

at the meeting, are available upon request to the 

Board of Governors of the Federal Reserve System, 

Washington, D.C. 20551. The minutes are published 

in the Federal Reserve Bulletin and in the Board’s 

annual report. 

detection for the identification and 

quantification of this analyte. The limit 

of quantitation (LOQ) for bifenazate in 

corn matrices and processed 

commodities was 0.01 ppm. The limit of 

detection (LOD) for the method is set at 

0.005 ppm. The method has also been 

validated by liquid chromatography/ 

mass spectrometry/mass spectroscopy 

(LC/MS/MS), and used for the 

confirmation of residues for corn raw 

agricultural commodities (RAC) and 

processed commodities. The analytical 

method for bifenazate and its major 

metabolite D3598, in animal tissues was 

designed using the same principles 

invoked in the plant method, with 

minor modifications. However, in 

animal tissue samples, a separate 

aliquot of the extract was used to 

determine residues of A1530, and its 

sulfate (combined) in milk and meat 

samples (as these metabolites appeared 

to be significant in the goat metabolism 

studies). The extract was subjected to 

acid hydrolysis to convert the sulfate 

conjugate to A1530, before it was 

quantified by LC/MS/MS. Another 

metabolite, D9569, was also monitored 

in milk by LC/MS/MS. Contact: Amer 

Al-Mudallal, (703) 605–0566; almudallal.amer@epa.gov. 

2. PP 8F7395. (EPA–HQ–OPP–2008–

0646). Valent U.S.A. Corporation, P.O. 

Box 8025, Walnut Creek, CA 94596 (as 

Agent for Sumitomo Chemical 

Company, Ltd.), proposes to establish a 

tolerance for residues of the insecticide 

clothianidin, (E)-1-(2-chloro-1,3-thiazol5-ylmethyl)-3-methyl-2-nitroguanidine, 

in or on almond, hull at 1.5 ppm; 

cotton, seed at 0.25 ppm; cotton, gin 

trash at 4.5 ppm; cotton, meal at 0.25 

ppm; cotton, hull at 0.25 ppm; cotton, 

refined oil at 0.01 ppm; soybean, seed 

at 0.03 ppm; soybean, hull at 0.35 ppm; 

soybean, meal at 0.07 ppm; soybean, oil 

at 0.01 ppm; tomato, paste at 0.08 ppm; 

tomato, puree at 0.07 ppm; nut, tree, 

group 14 at 0.01 ppm; vegetable, 

cucurbit, group 9 at 0.05 ppm; and 

vegetable, fruiting, group 8 at 0.25 ppm; 

and clothianidin, (E)-1-(2-chloro-1,3- 

thiazol-5-ylmethyl)-3-methyl-2- 

nitroguanidine and its metabolite, N-(2- 

chlorothiazol-5-ylmethyl)-N’- 

methylguanidine (TMG), in or on 

vegetable, leafy, brassica, group 5 at 3.0 

ppm; and vegetable, leafy, except 

brassica, group 4 at 3.5 ppm. Adequate 

enforcement methodology LC/MS/MS 

analysis is available to enforce the 

tolerance expression. Contact: Kable 

Davis, (703) 306–0415; 

davis.kable@epa.gov. 

New Exemption from an Inert Tolerance 

PP 8E7402. (EPA–HQ–OPP–2008–

0652). Falcon Lab, LLC, 1103 Norbee 

Drive, Wilmington, DE 19803, proposes 

to establish an exemption from the 

requirement of a tolerance in 40 CFR 

180.910 and 40 CFR 180.950 for 

residues of ammonium salts of higher 

fatty acids, [C8-C18 saturated and C8-C12

unsaturated, (CAS No. 84776–33–0)], 

when used as a pesticide inert 

ingredient in pesticide formulations in 

or on all food commodities. Because this 

petition is a request for an exemption 

from the requirement of a tolerance, no 

analytical method is required. Contact: 

Karen Samek, (703) 347–8825; 

samek.karen@epa.gov. 

List of Subjects 

Environmental protection, 

Agricultural commodities, Feed 

additives, Food additives, Pesticides 

and pests, Reporting and recordkeeping 

requirements. 

Dated: August 27, 2008. 

Donald R. Stubbs, 

Acting Director, Registration Division, Office 

of Pesticide Programs. 

[FR Doc. E8–20519 Filed 9–5–08; 8:45 am] 

BILLING CODE 6560–50–S 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisition of Shares of Bank or Bank 

Holding Companies 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire a bank or bank 

holding company. The factors that are 

considered in acting on the notices are 

set forth in paragraph 7 of the Act (12 

U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the office of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than 

September 22, 2008. 

A. Federal Reserve Bank of Chicago 

(Burl Thornton, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Harrison I. Steans, Bannockburn, 

Illinois, and Jennifer W. Steans, 

Evanston, Illinois, Financial 

Investments Corporation, PCB, LP, 

General Partners; Heather A. Steans; 

Robin M. Steans, all of Chicago, Illinois; 

Harrison I. Steans Self–Declaration of 

Revocable Trust – Harrison I. Steans, 

Trustee, both of Bannockburn, Illinois; 

Jennifer W. Steans 1999 Descendents 

Trust – James P. Kastenholz, Trustee, 

both of Evanston, Illinois; Heather A. 

Steans 1999 Descendants Trust – Leo A. 

Smith, Trustee; Robin M. Steans 1999 

Descendents Trust – Leonard A. Gail, 

Trustee, both of Chicago, Illinois; 

Jennifer W. Steans 2000 Trust – Jennifer 

W. Steans, Trustee, both of Evanston, 

Illinois; Heather A. Steans 2001 Trust –

Heather A. Steans, Trustee; Robin M. 

Steans Revocable Trust – Robin M. 

Steans, Trustee, both of Chicago, 

Illinois; James P. Kastenholz 2000 Trust 

– James P. Kastenholz, Trustee, both of 

Evanston, Illinois; Leonard A. Gail 

Revocable Trust – Leonard A. Gail, 

Trustee, both of Chicago, Illinois; 

Hunter Family Foundation – Thomas B. 

Hunter, III, and Maxine M. Hunter, 

Trustees; Maxine M. Hunter Charitable 

Lead Annuity Trust – Thomas B. 

Hunter, IV, all of Lake Forest, Illinois, 

and Willard M. Hunter, Trustees, Lake 

Bluff, Illinois; Thomas B. Hunter, III Self 

Declaration of Revocable Trust –

Thomas B. Hunter, III, Trustee; 

Morrison Family Foundation – Harold 

M. Morrison; Adeline S. Morrison, 

Trustees; Harold M. Morrison Trust –

Harold M. Morrison, Trustee, all of Lake 

Forest, Illinois; and USAmeriBancorp, 

Largo, Florida, to acquire voting shares 

of Taylor Capital Group, Rosemont, 

Illinois, and thereby indirectly acquire 

control of Cole Taylor Bank, Chicago, 

Illinois. 

Board of Governors of the Federal Reserve 

System, September 2, 2008. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E8–20583 Filed 9–4–08; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Federal Open Market Committee; 

Domestic Policy Directive of August 5, 

2008 

In accordance with § 271.25 of its 

rules regarding availability of 

information (12 CFR part 271), there is 

set forth below the domestic policy 

directive issued by the Federal Open 

Market Committee at its meeting held 

on August 5, 2008.1

The Federal Open Market Committee 

seeks monetary and financial conditions 

that will foster price stability and 

mstockstill on PROD1PC66 with NOTICES

51820 Federal Register / Vol. 73, No. 173 / Friday, September 5, 2008 / Notices 

promote sustainable growth in output. 

To further its long–run objectives, the 

Committee in the immediate future 

seeks conditions in reserve markets 

consistent with maintaining the federal 

funds rate at an average of around 2 

percent. 

By order of the Federal Open Market 

Committee, August 26, 2008. 

Brian F. Madigan, 

Secretary, Federal Open Market Committee. 

[FR Doc. E8–20558 Field 9–4–08; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL TRADE COMMISSION 

SES Performance Review Board 

AGENCY: Federal Trade Commission 

ACTION: Notice 

SUMMARY: Notice is hereby given of the 

appointment of members to the Federal 

Trade Commission’s Performance 

Review Board. 

FOR FURTHER INFORMATION CONTACT: 

Karen Leydon, Director of Human 

Resources, 600 Pennsylvania Avenue 

NW, Washington, DC 20580, (202) 326- 

2633. 

SUPPLEMENTARY INFORMATION: 

Publication of the Performance Review 

Board (PRB) membership is required by 

5 U.S.C. 4314 (c)(4). The PRB reviews 

and evaluates the initial appraisal of a 

senior executive’s performance by the 

supervisor, and makes 

recommendations regarding 

performance ratings, performance 

awards, and pay-for-performance pay 

adjustments to the FTC Chairman. 

The following individuals have been 

designated to serve on the FTC’s 

Performance Review Board: 

Charles H. Schneider, Chairman 

William Blumenthal 

Pauline M. Ippolito 

Lydia B. Parnes 

David P. Wales 

By direction of the Commission. 

Donald S. Clark 

Secretary 

[FR Doc. E8–20571 Filed 9–4–08: 8:45 am] 

BILLING CODE 6750–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10151 and CMS–

10152] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services. 

In compliance with the requirement 

of section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Centers for Medicare & Medicaid 

Services (CMS) is publishing the 

following summary of proposed 

collections for public comment. 

Interested persons are invited to send 

comments regarding this burden 

estimate or any other aspect of this 

collection of information, including any 

of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Data Collection 

for Medicare Beneficiaries Receiving 

Implantable Cardioverter-defibrillator 

for Primary Prevention of Sudden 

Cardiac Death; Use: The Centers for 

Medicare and Medicaid Services (CMS) 

provides coverage for implantable 

cardioverter-defibrillators (ICDs) for 

secondary prevention of sudden cardiac 

death based on extensive evidence 

showing that use of ICDs among patients 

with a certain set of physiologic 

conditions are effective. Accordingly, 

CMS considers coverage for ICDs 

reasonable and necessary under Section 

1862 (a)(1)(A) of the Social Security Act. 

However, evidence for use of ICDs for 

primary prevention of sudden cardiac 

death is less compelling for certain 

patients. 

To encourage responsible and 

appropriate use of ICDs, CMS issued a 

Decision Memo for Implantable 

Defibrillators on January 27, 2005, 

indicating that ICDs will be covered for 

primary prevention of sudden cardiac 

death if the beneficiary is enrolled in 

either an FDA-approved category B IDE 

clinical trial (42 CFR 405.201), a trial 

under the CMS Clinical Trial Policy 

(NCD Manual § 310.1) or a qualifying 

prospective data collection system 

(either a practical clinical trial or 

prospective systematic data collection, 

which is sometimes referred to as a 

registry). Form Number: CMS–10151 

(OMB# 0938–0967); Frequency: 

Reporting—Quarterly; Affected Public: 

Business or other for-profit and not-forprofit institutions; Number of 

Respondents: 1,217; Total Annual 

Responses: 50,000; Total Annual Hours: 

12,500. 

2. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Data collection 

for Medicare Beneficiaries Receiving 

FDG Positron Emission Tomography 

(PET) for Brain, Cervical, Ovarian, 

Pancreatic, Small Cell Lung, and All 

Other Cancers Use: In the Decision 

Memo #CAG–00181N issued on January 

27, 2005, CMS determined that the 

evidence is sufficient to conclude that 

for Medicare beneficiaries receiving 

FDG positron emission tomography 

(PET) for brain, cervical, ovarian, 

pancreatic, small cell lung, and 

testicular cancers is reasonable and 

necessary only when the provider is 

participating in and patients are 

enrolled in a systematic data collection 

project. CMS will consider prospective 

data collection systems to be qualified if 

they provide assurance that specific 

hypotheses are addressed and they 

collect appropriate data elements. The 

data collection should include baseline 

patient characteristics; indications for 

the PET scan; PET scan type and 

characteristics; FDG PET results; results 

of all other imaging studies; facility and 

provider characteristics; cancer type, 

grade, and stage; long-term patient 

outcomes; disease management changes; 

and anti-cancer treatment received. 

Form Number: CMS–10152 (OMB# 

0938–0968); Frequency: Reporting—On 

occasion; Affected Public: Business or 

other for-profit and not-for-profit 

institutions; Number of Respondents: 

2,000; Total Annual Responses: 50,000; 

Total Annual Hours: 4,167. 

To obtain copies of the supporting 

statement and any related forms for the 

proposed paperwork collections 

referenced above, access CMS’ Web Site 

at http://www.cms.hhs.gov/ 

PaperworkReductionActof1995, or Email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov, or call the 

Reports Clearance Office on (410) 786–

1326. 

In commenting on the proposed 

information collections please reference 

mstockstill on PROD1PC66 with NOTICES